{
    "clinical_study": {
        "@rank": "77103", 
        "arm_group": [
            {
                "arm_group_label": "Systane Family", 
                "arm_group_type": "Experimental", 
                "description": "Systane Lid Wipes administered to treated eye(s) twice a day; Systane Balance lubricant eye drops administered to treated eye(s), one drop four times a day; Systane Vitamins, two softgels ingested daily. Duration of treatment is 3 months."
            }, 
            {
                "arm_group_label": "Standard of Care", 
                "arm_group_type": "Active Comparator", 
                "description": "Microfiber towels (as warm compresses) warmed to the maximum comfortable temperature and placed over closed eyes for 8 minutes, one time a day. Duration of treatment is 3 months."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the efficacy of the Systane family of products\n      (Systane Lid Wipes, Systane Balance Lubricant Eye Drops, and Systane Vitamins) on meibomian\n      gland functionality in subjects with lipid deficiency related to evaporative dry eye as\n      compared to the standard of care warm compresses."
        }, 
        "brief_title": "Systane Family - Meibomian Deficiency", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Dry Eye Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Dry Eye Syndromes", 
                "Keratoconjunctivitis Sicca"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Must have a clinical diagnosis of lipid deficient Evaporative Dry Eye;\n\n          -  Meibomian Gland Functionality - Not more than 6 glands yielding liquid secretion;\n\n          -  Must be willing to discontinue the use of all other Meibomian Gland Dysfunction\n             management prior to receiving the study test article at Visit 1, up until the end of\n             the study period;\n\n          -  Must have best corrected visual acuity of 6/60 (20/20 Snellen, 1.0 logMAR) or better\n             in each eye;\n\n          -  Must be able to follow instructions and be willing and able to attend required study\n             visits;\n\n          -  Must read, sign, and date an Ethics Committee reviewed and approved informed consent\n             form;\n\n          -  Other protocol-defined inclusion criteria may apply.\n\n        Exclusion Criteria:\n\n          -  History or evidence of ocular or intraocular surgery or serious ocular trauma in\n             either eye within the past six months;\n\n          -  Current punctal occlusion of any type (e.g., collagen plugs, silicone plugs).\n\n          -  History of intolerance or hypersensitivity to any component of the study medications.\n\n          -  History or evidence of epithelial herpes simplex keratitis (dendritic keratitis);\n             vaccinia; active or recent varicella viral disease of the cornea and/or conjunctiva;\n             chronic bacterial disease of the cornea and/or conjunctiva and/or eyelids;\n             mycobacterial infection of the eye; and/or fungal disease of the eye.\n\n          -  Pregnant or lactating at the time of enrollment;\n\n          -  Not willing to take adequate precautions not to become pregnant during the study;\n\n          -  Use of any concomitant topical ocular medications during the study period;\n\n          -  Use of systemic medications that may contribute to dry eye unless on a stable dosing\n             regimen for a minimum of 30 days prior to Visit 1.\n\n          -  Ocular conditions that may preclude the safe administration of either drop under\n             investigation;\n\n          -  Unwilling to discontinue contact lens wear during the study period and for at least\n             one week prior to Visit 1;\n\n          -  Participation in an investigational drug or device study within 30 days of entering\n             this study;\n\n          -  Other protocol-defined exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "26", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01733745", 
            "org_study_id": "A00978"
        }, 
        "intervention": [
            {
                "arm_group_label": "Systane Family", 
                "description": "Systane Lid Wipes pre-moistened eyelid cleansing wipes for topical ocular external scrubbing of eyelids and eyelashes", 
                "intervention_name": "Systane Lid Wipes", 
                "intervention_type": "Other", 
                "other_name": "SYSTANE\u2122 LID WIPES"
            }, 
            {
                "arm_group_label": "Systane Family", 
                "intervention_name": "SYSTANE BALANCE Lubricant Eye Drops", 
                "intervention_type": "Other", 
                "other_name": "SYSTANE\u00ae BALANCE"
            }, 
            {
                "arm_group_label": "Systane Family", 
                "intervention_name": "Systane Vitamins", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "SYSTANE\u2122 Vitamin Omega-3 Supplement"
            }, 
            {
                "arm_group_label": "Standard of Care", 
                "intervention_name": "Microfiber towels", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Tetrahydrozoline", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "dry eye", 
            "lipid deficiency", 
            "meibomian gland"
        ], 
        "lastchanged_date": "September 26, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Fort Worth", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "76134"
                }, 
                "name": "Contact Alcon Call Center for Trial Locations"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Systane Family Efficacy in Meibomian Gland Functionality for Lipid Deficient Evaporative Dry Eye Subjects", 
        "overall_official": [
            {
                "affiliation": "Alcon Research", 
                "last_name": "Beth Scott, O.D., MS, FAAO", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Korb and Associates", 
                "last_name": "Donald R Korb, O.D.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Meibomian gland functionality will be evaluated by the investigator using the Meibomian Gland Evaluator (MGE), a handheld instrument that provides a standardized method for applying consistent, gentle pressure to the outer skin of the lower eyelid. The number of meibomian gland orificies evidencing liquid secretion during expression with the MGE will be documented.", 
            "measure": "Meibomian Glands Yielding Liquid Secretion (MGLYS)", 
            "safety_issue": "No", 
            "time_frame": "Month 3"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01733745"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The Standard Patient Evaluation of Eye Dryness (SPEED) Questionnaire is a 16-question validated questionnaire that measures the frequency and severity of dry eye symptoms. The SPEED questionnaire will be completed by the patient with no assistance from the office staff, physician, or anyone else.", 
                "measure": "Standard Patient Evaluation of Eye Dryness (SPEED) Questionnaire Responses", 
                "safety_issue": "No", 
                "time_frame": "Month 3"
            }, 
            {
                "description": "The Dry Eye OSDI Questionnaire is a 12-question validated questionnaire (resultant overall 0-100 score) that measures ocular symptoms, visual function, and environmental factors that may affect a patient's vision, where 0 = normal and 100 = severe. The OSDI questionnaire will be completed by the patient with no assistance from the office staff, physician, or anyone else.", 
                "measure": "Dry Eye Ocular Surface Disease Index (OSDI) Questionnaire Responses", 
                "safety_issue": "No", 
                "time_frame": "Month 3"
            }
        ], 
        "source": "Alcon Research", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alcon Research", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}